We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pozen, Inc., a pharmaceutical company focused primarily on products for the treatment of acute and chronic pain, migraine and other pain-related conditions, announced today the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a Marketing Authorization for MT 100 for the acute treatment of migraine.
Following a series of grim statistics in recent months, a new UN/WHO
report has confirmed that South Africa's AIDS programme is failing to deliver adequate life-saving treatment.
In the face of intensive government efforts to improve healthcare finances, French legislators have opted to reduce the forthcoming sales tax on pharmaceuticals from 1.96% to 1.76%.
Leading private equity firm Direct Capital has acquired a shareholding of 51% in New Zealand Pharmaceuticals (NZP), which produces specialty chemicals for some of the world's leading pharmaceutical and biotechnology companies.
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) and Micromet AG (private) today announced an agreement to end the companies' collaboration to identify and develop antibody-based therapeutics for the treatment of inflammatory and autoimmune diseases.